Leukopaks are highly-enriched leukapheresis-derived products obtained from an IRB-approved collection facility. Leukopaks contain higher concentrations of mononuclear cells, B cells, T cells, stem/progenitor cells, dendritic cells, and other cell types as compared to standard venipuncture collection methods or buffy coat products. Healthy, consented donors undergo a medical screening evaluation and are administered 5 doses of 10ug/kg TBW of Neupogen (filgrastim) on each of 5 days and two 240ug/kg TBW doses of Mozobil (plerixafor) on days 4 and 5 per IRB approved protocols prior to Leukapheresis. Leukapheresis is performed on the day of the 5th filgrastim dose following plerixafor administration and the next day using the Spectra Optia® Apheresis System. MNC rich cells, enriched with CD34+ cells mobilized into peripheral blood, are continuously collected from 2-2.5 donor blood volumes with ACD-A as an anticoagulant. Approximately 120mL of autologous plasma is automatically collected directly into the cell pool following leukapheresis. A nominal, post quality sampling, calculated volume of 290mL in a sterile transfer bag constitutes this product . Cell counts and CD34 quantities will vary based on the donor's response to mobilization. The total nucleated cell count is determined using AO/PI from the combined pool and provided as information. Fresh Mobilized leukapheresis products typically contain up to 1 % CD34+ cells, 40% granulocytes, and 5 % hematocrit. Exact percentages will vary from donor to donor.
English
Deutsch
